Successful Treatment of Recalcitrant Melasma with Picolaser and Isobionicamide-Cysteamine Combination.

Corey L Hartman, Michaela Crawford, Cheri Frey, Rawn Bosley, Riccardo Sfriso, Laure Dirlewanger, Behrooz Kasraee

Abstract readCase Reports

In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Corey L HartmanDr. Hartman is with Skin Wellness Dermatology in Birmingham, Alabama, and the Department of Dermatology at the University of Alabama Heersink School of Medicine in Birmingham, Alabama.

Michaela CrawfordMs. Crawford is with the Meharry Medical College School of Medicine in Nashville, Tennessee.

Cheri FreyDr. Frey is with the Department of Dermatology at Howard University in Washington, District of Columbia.

Rawn BosleyDr. Bosley is with Signature Dermatology and Aesthetics in Grapevine, Texas.

Riccardo SfrisoDr. Sfriso and Ms. Dirlewanger are with Scientis SA in Geneva, Switzerland.

Laure DirlewangerDr. Sfriso and Ms. Dirlewanger are with Scientis SA in Geneva, Switzerland.

Behrooz KasraeeDr. Kasraee is with Scientis SA in Geneva, Switzerland and Centre de Dermatologie de Cornavin in Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melasma is a highly recurrent disorder that is challenging to treat and significantly affects the quality of life of patients. Cysteamine is an endogenous antioxidant produced during the coenzyme A metabolism cycle and is naturally present in all mammalian cells. The depigmenting efficacy of topical cysteamine has been shown in several double-blind, randomized, placebo-controlled clinical trials. Isobionicamide is a derivative of vitamin B3 and a new depigmenting agent that inhibits melanosomal transfer and was found to potentiate cysteamine's inhibitory effect on tyrosinase. Picosecond lasers have been shown to be effective in treating melasma in dark-skinned individuals. Herein, we report the case of a 50-year-old patient (phototype V) with recalcitrant melasma who significantly responded to picosecond laser associated with the topical application of isobionicamide-cysteamine.

Indexed as

combination treatmentcysteaminehyperpigmentationisobionicamidelaserMelasma

Identifiers

PMID40078863

PMCPMC11896620

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.